Molecular targeting regulation of proliferation and differentiation of the bone marrow-derived mesenchymal stem cells or mesenchymal stromal cells

Current Drug Targets

Volumn 13, Issue 4, 2012, Pages 561-571

  Chen, Bei Yu ^a   Wang, Xi ^b   Chen, Liang Wei ^b   Luo, Zhuo Jing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow derived Msc; Immune modulation; Molecular targeting; Msc therapy; Tumorigenicity

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL SURFACE MARKER; CYCLIC AMP DEPENDENT PROTEIN KINASE; FIBROBLAST GROWTH FACTOR; FRIZZLED PROTEIN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; SMAD PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ADIPOGENESIS; ARTICLE; BONE DISEASE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL INTERACTION; CELL ISOLATION; CELL MIGRATION; CELL ONCOGENE; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CHONDROPATHY; DEGENERATIVE DISEASE; EMBRYONIC STEM CELL; GENE TARGETING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOLECULARLY TARGETED THERAPY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; STEM CELL EXPANSION;

ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MESENCHYMAL STROMAL CELLS; SIGNAL TRANSDUCTION; TISSUE ENGINEERING;

EID: 84863250460     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799499749     Document Type: Article

References (125)

1. Satija NK, Gurudutta GU, Sharma S, et al. Mesenchymal stem cells: molecular targets for tissue engineering. Stem Cells Dev 2007; 1: 7-23.
2. Valtieri M, Sorrentino A. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol 2008; 217: 296-300.
3. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
4. Pevsner-Fischer M, Levin S, Zipori D. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Rev 2011; 7: 560-8.
5. Trivedi P, Hematti P. Simultaneous generation of CD34+ primitive hematopoietic cells and CD73+ mesenchymal stem cells from human embryonic stem cells cocultured with murine OP9 stromal cells. Exp Hematol 2007; 35: 146-54.
6. Sorrentino A, Ferracin M, Castelli G, et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol 2008; 36: 1035-46.
7. Tormin A, Li O, Brune JC, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood 2011; 117: 5067-77.
8. Grazia TJ, Plenter RJ, Lepper HM, et al. Prolongation of cardiac allograft survival by a novel population of autologous CD117+ bone marrow-derived progenitor cells. Am J Transplant 2011; 11: 34-44.
9. Pasquinelli G, Pacilli A, Alviano F, et al. Multidistrict human mesenchymal vascular cells: pluripotency and stemness characteristics. Cytotherapy 2010; 12: 275-87.
10. Mareddy S, Dhaliwal N, Crawford R, Xiao Y. Stem cell-related gene expression in clonal populations of mesenchymal stromal cells from bone marrow. Tissue Eng Part A 2010; 16: 749-58.
11. [] Celebi B, Elçin YM. Proteome analysis of rat bone marrow mesenchymal stem cell subcultures. J Proteome Res 2009; 8: 2164-2172.
12. Jaishankar A, Barthelery M, Freeman WM, Salli U, Ritty TM, Vrana KE. Human embryonic and mesenchymal stem cells express different nuclear proteomes. Stem Cells Dev 2009; 18: 793-802.
13. Delorme B, Ringe J, Pontikoglou C, et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 2009; 27: 1142-51.
14. Tan J, Huang H, Huang W, et al. The genomic landscapes of histone H3-Lys9 modifications of gene promoter regions and expression profiles in human bone marrow mesenchymal stem cells. J Genet Genomics 2008; 35: 585-93.
15. Vater C, Kasten P, Stiehler M. Culture media for the differentiation of mesenchymal stromal cells. Acta Biomater 2011; 7: 463-77.
16. Widelitz R. Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors 2005; 23: 111-6.
17. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423: 448-52.
18. Prakash N, Wurst W. A Wnt signal regulates stem cell fate and differentiation in vivo. Neurodegener Dis 2007; 4: 333-8.
19. Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene 2009; 433: 1-7.
20. De Boer J, Wang HJ, Van Blitterswijk C. Effects of Wnt signaling on proliferation and differentiation of human mesenchymal stem cells. Tissue Eng 2004; 10: 393-401.
21. [Petrov N, Zhidkova O, Serikov V, Zenin V, Popov B. Induction of Wnt/β-Catenin Signaling in Mouse Mesenchymal Stem Cells Is Associated with Activation of the p130 and E2f4 and Formation of the p130/Gsk3β/β-Catenin Complex. Stem Cells Dev 2011; [Epub ahead of print].
22. Takada I, Kouzmenko AP, Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 2009; 5: 442-7.
23. [] Cawthorn WP, Bree AJ, Yao Y, et al. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β-catenin-dependent mechanism. Bone 2011; [Epub ahead of print].
24. Shang YC, Wang SH, Xiong F, et al. Wnt3a signaling promotes proliferation, myogenic differentiation, and migration of rat bone marrow mesenchymal stem cells. Acta Pharmacol Sin 2007; 28: 1761-74.
25. Shang YC, Zhang C, Wang SH, et al. Activated beta-catenin induces myogenesis and inhibits adipogenesis in BM-derived mesenchymal stromal cells. Cytotherapy 2007; 9: 667-81.
26. Karow M, Popp T, Egea V, Ries C, Jochum M, Neth P. Wnt signalling in mouse mesenchymal stem cells: impact on proliferation, invasion and MMP expression. J Cell Mol Med 2009; 13: 2506-20.
27. Rodríguez-Carballo E, Ulsamer A, Susperregui AR, et al. Conserved regulatory motifs in osteogenic gene promoters integrate cooperative effects of canonical Wnt and BMP pathways. J Bone Miner Res 2011; 26: 718-29.
28. Zhang JF, Li G, Chan CY, et al. Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway. Mol Cell Endocrinol 2010; 314: 70-4.
29. Tang M, Miyamoto Y, Huang EJ. Multiple roles of beta-catenin in controlling the neurogenic niche for midbrain dopamine neurons. Development 2009; 136: 2027-38.
30. Lie DC, Colamarino SA, Song HJ, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature 2005; 437: 1370-5.
31. Castelo-Branco G, Andersson ER, Minina E, et al. Delayed dopaminergic neuron differentiation in Lrp6 mutant mice. Dev Dyn 2010; 239: 211-21.
32. Castelo-Branco G, Wagner J, Rodriguez FJ, et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci USA 2003; 100: 12747-12752.
33. Chung S, Leung A, Han BS, et al. Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell 2009; 5: 646-58.
34. Sousa KM, Villaescusa JC, Cajanek L, et al. Wnt2 regulates progenitor proliferation in the developing ventral midbrain. J Biol Chem 2010; 285: 7246-53.
35. Andersson ER, Prakash N, Cajanek L, et al. Wnt5a regulates ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in vivo. PLoS One 2008; 3: e3517.
36. Schulte G, Bryja V, Rawal N, Castelo-Branco G, Sousa KM, Arenas E. Purified Wnt-5a increases differentiation of midbrain dopaminergic cells and dishevelled phosphorylation. J Neurochem 2005; 92: 1550-3.
37. Parish CL, Castelo-Branco G, Rawal N, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest 2008; 118: 149-160.
38. Chiba S. Notch signaling in stem cell systems. Stem Cells 2006; 24: 2437-47.
39. Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442: 823-6.
40. Dong Y, Jesse AM, Kohn A, et al. RBPj kappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development 2010; 137: 1461-71.
41. Das D, Lanner F, Main H, et al. Notch induces cyclin-D1-dependent proliferation during a specific temporal window of neural differentiation in ES cells. Dev Biol 2010; 348: 153-66.
42. Schroeder T, Just U. mNotch1 signaling reduces proliferation of myeloid progenitor cells by altering cell-cycle kinetics. Exp Hematol 2000; 28: 1206-13.
43. Ehm O, Göritz C, Covic M, et al. RBPJ kappa-dependent signaling is essential for long-term maintenance of neural stem cells in the adult hippocampus. J Neurosci 2010; 30: 13794-13807.
44. Wang Y, Tu W, Lou Y, et al. Mesenchymal stem cells regulate the proliferation and differentiation of neural stem cells through Notch signaling. Cell Biol Int 2009; 33: 1173-9.
45. Robinson AP, Foraker JE, Ylostalo J, Prockop DJ. Human stem/progenitor cells from bone marrow enhance glial differentiation of rat neural stem cells: a role for transforming growth factor β and Notch signaling. Stem Cells Dev 2011; 20: 289-300.
46. Chen C, Zhang Y. Notch signaling in differentiation of mesenchymal stem cells (in Chinese). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18: 510-4.
47. Mareddy S, Dhaliwal N, Crawford R, Xiao Y. Stem cell-related gene expression in clonal populations of mesenchymal stromal cells from bone marrow. Tissue Eng Part A 2010; 16: 749-58.
48. Kim WK, Meliton V, Tetradis S, et al. Osteogenic oxysterol, 20(S)-hydroxycholesterol, induces notch target gene expression in bone marrow stromal cells. J Bone Miner Res 2010; 25: 782-95.
49. Li Y, Hiroi Y, Ngoy S, et al. Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation 2011; 123: 866-76.
50. Kurpinski K, Lam H, Chu J, et al. Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cells 2010; 28: 734-42.
51. Jing L, Jia Y, Lu J, et al. MicroRNA-9 promotes differentiation of mouse bone mesenchymal stem cells into neurons by Notch signaling. Neuroreport 2011; 22: 206-11.
52. Kim WK, Meliton V, Bourquard N, Hahn TJ, Parhami F. Hedgehog signaling and osteogenic differentiation in multipotent bone marrow stromal cells are inhibited by oxidative stress. J Cell Biochem 2010; 111: 1199-209.
53. Trzaska KA, Rameshwar P. Dopaminergic neuronal differentiation protocol for human mesenchymal stem cells. Methods Mol Biol 2011; 698: 295-303.
54. Duncan AW, Rattis FM, DiMascio LN, et al. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 2005; 6: 314-22.
55. Zhou K, Huang L, Zhou Z, et al. Wnt and Notch signaling pathways selectively regulating hematopoiesis. Ann Hematol 2010; 89: 749-57.
56. Tang M, Villaescusa JC, Luo SX, et al. Interactions of Wnt/beta-catenin signaling and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. J Neurosci 2010; 30: 9280-91.
57. Day TF, Yang Y. Wnt and hedgehog signaling pathways in bone development. J Bone Joint Surg Am 2008; 90 Suppl 1: 19-24.
58. Lin GL, Hankenson KD. Integration of BMP, Wnt, and Notch signaling pathways in osteoblast differentiation. J Cell Biochem 2011; 112: 3491-501
59. Luu HH, Song WX, Luo X, et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 2007; 25: 665-77.
60. Martinovic S, Mazic S, Kisic V, et al. Expression of bone morphogenetic proteins in stromal cells from human bone marrow long-term culture. J Histochem Cytochem 2004; 52: 1159-67.
61. Jensen ED, Pham L, Billington CJ Jr, et al. Bone morphogenic protein 2 directly enhances differentiation of murine osteoclast precursors. J Cell Biochem 2010; 109: 672-82.
62. Lou J, Tu Y, Li S, Manske PR. Involvement of ERK in BMP-2 induced osteoblastic differentiation of mesenchymal progenitor cell line C3H10T1/2. Biochem Biophys Res Commun 2000; 268: 757-62.
63. Choi, Y.A., Kang, S.S. and Jin, E.J. (2009) BMP-2 treatment of C3H10T1/2 mesenchymal cells blocks MMP-9 activity during chondrocyte commitment. Cell Biol. Int., 33, 887-892.
64. Jäger M, Fischer J, Dohrn W, et al. Dexamethasone modulates BMP-2 effects on mesenchymal stem cells in vitro. J Orthop Res 2008; 26: 1440-8.
65. Li J, Khavandgar Z, Lin SH, Murshed M. Lithium chloride attenuates BMP-2 signaling and inhibits osteogenic differentiation through a novel WNT/GSK3-beta independent mechanism. Bone 2011; 48: 321-31.
66. Ghayor C, Ehrbar M, San Miguel B, Grätz KW, Weber FE. CAMP enhances BMP2-signaling through PKA and MKP1-dependent mechanisms. Biochem Biophys Res Commun 2009; 381: 247-52.
67. [Lavery K, Swain P, Falb D, Alaoui-Ismaili MH. BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J Biol Chem 2008; 283: 20948-20958.
68. Lavery K, Hawley S, Swain P, Rooney R, Falb D, Alaoui-Ismaili MH. New insights into BMP-7 mediated osteoblastic differentiation of primary human mesenchymal stem cells. Bone 2009; 45: 27-41.
69. Shen B, Wei A, Whittaker S, et al. The role of BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in vitro. J Cell Biochem 2010; 109: 406-16.
70. Sammons J, Ahmed N, El-Sheemy M, Hassan HT. The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev 2004; 13: 273-80.
71. Tang N, Song WX, Luo J, et al. BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 2009; 13: 2448-64.
72. Ahmed N, Sammons J, Carson RJ, Khokher MA, Hassan HT. Effect of bone morphogenetic protein-6 on haemopoietic stem cells and cytokine production in normal human bone marrow stroma. Cell Biol Int 2001; 25: 429-35.
73. Nochi H, Sung JH, Lou J, et al. Adenovirus mediated BMP-13 gene transfer induces chondrogenic differentiation of murine mesenchymal progenitor cells. J Bone Miner Res 2004; 19: 111-22.
74. Wang QW, Chen ZL, Piao YJ. Mesenchymal stem cells differentiate into tenocytes by bone morphogenetic protein (BMP) 12 gene transfer. J Biosci Bioeng 2005; 100: 418-22.
75. Stewart A, Guan H, Yang K. BMP-3 promotes mesenchymal stem cell proliferation through the TGF-beta/activin signaling pathway. J Cell Physiol 2010; 223: 658-66.
76. Hatakeyama Y, Nguyen J, Wang X, Nuckolls GH, Shum L. Smad signaling in mesenchymal and chondroprogenitor cells. J Bone Joint Surg Am 2003; 85-A Suppl 3: 13-8.
77. Ju W, Hoffmann A, Verschueren K, et al. The bone morphogenetic protein 2 signaling mediator Smad1 participates predominantly in osteogenic and not in chondrogenic differentiation in mesenchymal progenitors C3H10T1/2. J Bone Miner Res 2000; 15: 1889-99.
78. Lee KS, Kim HJ, Li QL, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20: 8783-92.
79. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 2004; 279: 40267-40275.
80. Miraoui H, Severe N, Vaudin P, Pagès JC, Marie PJ. Molecular silencing of Twist1 enhances osteogenic differentiation of murine mesenchymal stem cells: implication of FGFR2 signaling. J Cell Biochem 2010; 110: 1147-54.
81. Mizuno Y, Yagi K, Tokuzawa Y, et al. MiR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochem Biophys Res Commun 2008; 368: 267-72.
82. Chau JF, Leong WF, Li B. Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol 2009; 24: 1593-606.
83. Trzaska KA, King CC, Li KY, et al. Brain-derived neurotrophic factor facilitates maturation of mesenchymal stem cell-derived dopamine progenitors to functional neurons. J Neurochem 2009; 110, 1058-1069.
84. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230-2.
85. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, Welter JF. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol 2005; 203: 398-409.
86. Farré J, Roura S, Prat-Vidal C, et al. FGF-4 increases in vitro expansion rate of human adult bone marrow-derived mesenchymal stem cells. Growth Factors 2007; 25: 71-6.
87. Rider DA, Dombrowski C, Sawyer AA, et al. Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells. Stem Cells 2008; 26: 1598-608.
88. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem 2009; 284: 4897-904.
89. Hamidouche Z, Fromigué O, Nuber U, et al. Autocrine fibroblast growth factor 18 mediates dexamethasone-induced osteogenic differentiation of murine mesenchymal stem cells. J Cell Physiol 2010; 224: 509-15.
90. Kawano S, Otsu K, Kuruma A, et al. ATP autocrine/paracrine signaling induces calcium oscillations and NFAT activation in human mesenchymal stem cells. Cell Calcium 2006; 39: 313-24.
91. Sanz C, Vázquez P, Blázquez C, Barrio PA, Alvarez Mdel M, Blázquez E. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab 2010; 298: E634-43.
92. Forte G, Minieri M, Cossa P, et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006; 24: 23-33.
93. Shin MK, Kim MK, Bae YS, et al. A novel collagen-binding peptide promotes osteogenic differentiation via Ca2+/calmodulin-dependent protein kinase II/ERK/AP-1 signaling pathway in human bone marrow-derived mesenchymal stem cells. Cell Signal 2008; 20: 613-24.
94. Kazemnejad S, Allameh A, Gharehbaghian A, Soleimani M, Amirizadeh N, Jazayeri M. Efficient replacing of fetal bovine serum with human platelet releasate during propagation and differentiation of human bone-marrow-derived mesenchymal stem cells to functional hepatocyte-like cells. Vox Sang 2008; 95: 149-58.
95. Schutze N, Noth U, Schneidereit J, Hendrich C, Jakob F. Differential expression of CCN-family members in primary human bone marrow-derived mesenchymal stem cells during osteogenic, chondrogenic and adipogenic differentiation. Cell Commun Signal 2005; 3: 5.
96. Ortuño MJ, Ruiz-Gaspà S, Rodríguez-Carballo E, et al. p38 regulates expression of osteoblast-specific genes by phosphorylation of osterix. J Biol Chem 2010; 285: 31985-31994.
97. Abdallah BM, Boissy P, Tan Q, et al. dlk1/FA1 regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of pro-inflammatory cytokines and immune response-related factors. J Biol Chem 2007; 282: 7339-51.
98. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol 2008; 215: 442-51.
99. Saleh FA, Whyte M, Ashton P, Genever PG. Regulation of mesenchymal stem cell activity by endothelial cells. Stem Cells Dev 2011; 20: 391-403.
100. Chen XD. Extracellular matrix provides an optimal niche for the maintenance and propagation of mesenchymal stem cells. Birth Defects Res C Embryo Today 2010; 90: 45-54.
101. Luo W, Shitaye H, Friedman M, et al. Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation. Exp Cell Res 2008; 314: 3382-91.
102. Barrilleaux BL, Phinney DG, Fischer-Valuck BW, et al. Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells. Tissue Eng Part A 2009; 15: 2335-46.
103. Kim WK, Meliton V, Tetradis S, et al. Osteogenic oxysterol, 20(S)-hydroxycholesterol, induces notch target gene expression in bone marrow stromal cells. J Bone Miner Res 2010; 25: 782-95.
104. Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, Prockop DJ. Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem 2005; 280: 2309-23.
105. Kim WK, Meliton V, Bourquard N, Hahn TJ, Parhami F. Hedgehog signaling and osteogenic differentiation in multipotent bone marrow stromal cells are inhibited by oxidative stress. J Cell Biochem 2010; 111: 1199-209.
106. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009; 27: 1050-6.
107. Siebzehnrubl FA, Jeske I, Müller D, et al. Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells. Brain Pathol 2009; 19: 399-408.
108. Casalbore P, Budoni1 M, Ricci-Vitiani L, et al. Tumorigenic potential of olfactory bulb-derived human adult neural stem cells associates with activation of TERT and NOTCH1. PLoS One 2009; 4: e4434.
109. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6: 221-30.
110. Røsland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 2009; 69: 5331-9.
111. Jeong JO, Han JW, Kim JM, et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res 2011; 108: 1340-7.
112. Zhou XG, Yang Y, Yang JS, et al. Granulocyte-macrophage colony-stimulating factor and interleukin 4 induce the malignant transformation of the bone marrow-derived human adult mesenchymal stem cells. Chin Med J 2011; 124: 729-33.
113. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
114. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010; 28: 1568-70.
115. Teng IW, Hou PC, Lee KD, et al. Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancerstem/initiating cells. Cancer Res 2011; 71: 4653-63.
116. Dressel R, Schindehütte J, Kuhlmann T, et al. The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients' immune response. PLoS One 2008; 3: e2622.
117. [] Abumaree M, Al Jumah M, Pace RA, Kalionis B. Immunosuppressive Properties of Mesenchymal Stem Cells. Stem Cell Rev 2011 [Epub ahead of print]
118. Nasef A, Ashammakhi N, Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008; 3: 531-546.
119. Sundin M, D'arcy P, Johansson CC, et al. Multipotent mesenchymal stromal cells express FoxP3: a marker for the immunosuppressive capacity? J Immunother 2011; 34: 336-42.
120. Kuçi Z, Kuçi S, Zircher S, et al. Mesenchymal stromal cells derived from CD271(+) bone marrow mononuclear cells exert potent allosuppressive properties. Cytotherapy 2011; 13: 1193-204
121. Yagi H, Soto-Gutierrez A, Parekkadan B, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant 2010; 19: 667-79.
122. Park MJ, Shin JS, Kim YH, et al. Murine mesenchymal stem cells suppress T lymphocyte activation through IL-2 receptor α (CD25) cleavage by producing matrix metalloproteinases. Stem Cell Rev 2011; 7: 381-93.
123. Lei J, Wang Z, Hui D, et al. Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. Cell Immunol 2011; 271: 147-56.
124. Kassis I, Vaknin-Dembinsky A, Karussis D. Bone marrow mesenchymal stem cells: agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther 2011; 6: 63-8.
125. Meyer AK, Maisel M, Hermann A, Stirl K, Storch A. Restorative approaches in Parkinson's disease: which cell type wins the race? J Neurol Sci 2010; 289: 93-103.